The Product Development for Vaccines Advisory Committee (PDVAC) provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies. Its remit includes the prioritisation of target pathogens for vaccine and/or monoclonal antibody development and technology platforms, in addition to oversight of the development of preferred product characteristics (PPCs), technical/R&D roadmaps, full vaccine value assessments and consultations on product development pathways.
The 2024 meeting took place in Geneva from 9-11 December (open meeting) and 12 December (closed meeting).
An executive summary of the meeting will be made available in due course.
Presentations
Day 1
Keynote: From PDVAC prioritization to policy - 10 years of action on RSV - E. Sparrow
Context for and goals of this PDVAC meeting - B. Giersing
Immunization Agenda 20230 (IA2030) Strategic Priority 7 (SP7) - M. Sheel; KP Asante
Outcomes from the Gavi vaccine Investment Strategy (VIS) - M. Tufet
Development of a Strategic Framework for Novel Combination Vaccines - B. Hausdorff
Strategies to accelerate vaccine approval and de-risk investments - D. King
Updates from International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) - P. Barbosa
Updates from Developing Countries Vaccine Manufacturers Network (DCVMN) - R. Suri
Updates from other WHO committees - J. Hombach; T. Prasad; P. Lambach; I. Knezevic
VIPS and Vaccine MAPs - M. Menozzi-Arnaud; M. Hasso-Agopsowicz; D. Zehrung; C. Jarrahian
Overview of progress in STI vaccines - S. Gottlieb
Day 2
Where are we with mRNA and regional vaccine production? - M. Friede
Next generation influenza vaccines - P. Gsell; P. Lambach; J. Taaffe
Monoclonal antibodies - E. Sparrow; A. Cameron; I. James
Group A Strep - P. Gsell; A. Steer; A. Beaton; A. Wilder-Smith
Group B Strep vaccines - A. Wilder-Smith; K. Le Doare
New Tuberculosis vaccines for adults and adolescents - W. Hanekom; A. Ginsberg; M. Hatherill; G. Churchyard; R. White; B. Giersing
Day 3
Update on the impact of vaccines on AMR - M. Hasso-Agopsowicz
Shigella vaccines - A. Wilder-Smith; C MacLennan; R. Kaminski; J. Platts-Mills
Norovirus vaccines update - C. Kirkwood; D. Steele
Next generation rotavirus vaccines update - C. Kirkwood; D. Steele
iNTS vaccines - A. Wilder-Smith
Bivalent Salmonella Typhi/Paratyphi A - A. Wilder-Smith; A. Pollard; A.-B. Ibarz-Pavon